Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBITDA: 2018-2024

Historic EBITDA for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to -$80.9 million.

  • Arcturus Therapeutics Holdings' EBITDA fell 94.81% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.49%. This contributed to the annual value of -$80.9 million for FY2024, which is 172.30% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its EBITDA stood at -$80.9 million for FY2024, which was down 172.30% from -$29.7 million recorded in FY2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' EBITDA registered a high of $9.3 million during FY2022, and its lowest value of -$203.7 million during FY2021.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median EBITDA value was -$29.7 million (recorded in 2023), while the average stood at -$33.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 104.59% in 2022, then tumbled by 417.95% in 2023.
  • Yearly analysis of 5 years shows Arcturus Therapeutics Holdings' EBITDA stood at -$72.1 million in 2020, then slumped by 182.30% to -$203.7 million in 2021, then skyrocketed by 104.59% to $9.3 million in 2022, then plummeted by 417.95% to -$29.7 million in 2023, then slumped by 172.30% to -$80.9 million in 2024.